Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Hyon Choi received his rheumatology fellowship training at Massachusetts General Hospital and Harvard Medical School, and his master's and doctorate degrees in epidemiology from Harvard University. Dr. Choi has been a leading clinical rheumatologist and investigator with a primary focus on gout, rheumatoid arthritis, and psoriatic arthritis throughout his academic career, as reflected by his funding (National Institutes of Health [NIH] and industry), publications (over 200, including >60 gout-related peer-reviewed papers including those published in NEJM, JAMA, Lancet, Nat Genet, Ann Int Med, BMJ, Arch Int Med, Am J Med, Ann Rheum Dis, A&R), and reviewer activities for top journals and the NIH. The significance of Dr. Choi?s contributions has been widely accepted by the field, and his findings have been referenced by many articles as well as by the recent guidelines from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR, 2012). His clinical and epidemiologic research has provided state-of-the-art evidence to inform the gout field, which is needed to move its guidelines from expert-consensus to an evidence-based approach.
View my most recent publications at PubMed
A study led by Massachusetts General Hospital investigators suggests that following a diet known to reduce the risk of hypertension and cardiovascular disease may also reduce the risk of gout.
A new Massachusetts General Hospital study finds that, while hospitalizations related to rheumatoid arthritis have dropped considerably over the past two decades, hospitalizations primarily associated with gout have increased dramatically The results reflect improved management of rheumatoid arthritis and both an increased prevalence and persistent suboptimal care of gout.
A study led by a Massachusetts General Hospital investigator finds significant racial disparities in the risk that patients being treated with the most commonly prescribed medication for gout will develop a serious, sometimes life-threatening adverse reaction, a risk that closely correlates with the frequency of a gene variant previously associated with that reaction.
Back to Top